Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

In vitro screening for drug repositioning.

Wilkinson GF, Pritchard K.

J Biomol Screen. 2015 Feb;20(2):167-79. doi: 10.1177/1087057114563024. Epub 2014 Dec 19. Review.

PMID:
25527136
2.

Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

Coopman K, Wallis R, Robb G, Brown AJ, Wilkinson GF, Timms D, Willars GB.

Mol Endocrinol. 2011 Oct;25(10):1804-18. doi: 10.1210/me.2011-1160. Epub 2011 Aug 25.

3.

Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, Willars GB.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):795-808. doi: 10.1124/jpet.110.166009. Epub 2010 May 27.

4.

Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor.

Huang Y, Wilkinson GF, Willars GB.

Br J Pharmacol. 2010 Jan;159(1):237-51. doi: 10.1111/j.1476-5381.2009.00517.x. Epub 2009 Nov 27.

5.

Full and partial agonists of muscarinic M3 receptors reveal single and oscillatory Ca2+ responses by beta 2-adrenoceptors.

Kurian N, Hall CJ, Wilkinson GF, Sullivan M, Tobin AB, Willars GB.

J Pharmacol Exp Ther. 2009 Aug;330(2):502-12. doi: 10.1124/jpet.109.153619. Epub 2009 May 6.

6.

Agouti-related protein (83-132) is a competitive antagonist at the human melanocortin-4 receptor: no evidence for differential interactions with pro-opiomelanocortin-derived ligands.

Pritchard LE, Armstrong D, Davies N, Oliver RL, Schmitz CA, Brennand JC, Wilkinson GF, White A.

J Endocrinol. 2004 Jan;180(1):183-91.

PMID:
14709157
8.

Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+.

Werry TD, Wilkinson GF, Willars GB.

Biochem J. 2003 Sep 1;374(Pt 2):281-96. Review.

9.

Ca(2+) signalling by recombinant human CXCR2 chemokine receptors is potentiated by P2Y nucleotide receptors in HEK cells.

Werry TD, Christie MI, Dainty IA, Wilkinson GF, Willars GB.

Br J Pharmacol. 2002 Mar;135(5):1199-208.

11.
12.

Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor.

Wilkinson GF, Thurlow RJ, Sellers LA, Coote JE, Feniuk W, Humphrey PP.

Br J Pharmacol. 1996 Jun;118(3):445-7.

13.

Calcium signalling in human colonic epithelial cells via tyrosine kinase and G-protein linked receptors.

Wilkinson GF, Feniuk W, Sellers LA, Humphrey PP.

Biochem Soc Trans. 1995 Aug;23(3):459S. No abstract available.

PMID:
8566351
14.

Stimulation of nitric oxide synthase by endothelial purinoceptors does not correlate with inositol trisphosphate levels.

Brown CA, Wilkinson GF, Boarder MR.

Biochem Soc Trans. 1995 Aug;23(3):425S. No abstract available.

PMID:
8566313
15.

Binding of [35S]adenosine 5'-O-(2-thiodiphosphate) to endothelial cells in culture.

Wilkinson GF, Boarder MR.

Biochem Pharmacol. 1995 May 17;49(10):1411-8.

PMID:
7763284
16.

G protein-coupled P2 purinoceptors: from molecular biology to functional responses.

Boarder MR, Weisman GA, Turner JT, Wilkinson GF.

Trends Pharmacol Sci. 1995 Apr;16(4):133-9. Review.

PMID:
7610499
18.

Stimulation of phospholipase C in cultured microvascular endothelial cells from human frontal lobe by histamine, endothelin and purinoceptor agonists.

Purkiss JR, West D, Wilkes LC, Scott C, Yarrow P, Wilkinson GF, Boarder MR.

Br J Pharmacol. 1994 Apr;111(4):1041-6.

20.
21.
23.

Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig.

Paciorek PM, Cowlrick IS, Perkins RS, Taylor JC, Wilkinson GF, Waterfall JF.

Br J Pharmacol. 1990 Jun;100(2):289-94.

Supplemental Content

Loading ...
Support Center